– IRELAND, Dublin – Nuritas, a biotech start-up using artificial intelligence to revolutionise therapeutics discovery, announced today the appointment of former Novartis Division Head, Dr George Gunn, as Chairman of the company’s Board of Directors.
Dr Gunn brings huge experience and connectivity to the position having been a member of the Novartis Global Executive Committee and Head of the Novartis Animal Health Division from 2004 until early 2015. He also served as Division Head for Novartis Consumer Health from 2008 to 2011 and was the Head of Corporate Social Responsibility for Novartis from 2011 to 2014.
Prior to Novartis, Dr Gunn practiced veterinary medicine for nine years before working at Johnson and Johnson and Pharmacia in an array of increasingly senior executive healthcare roles. George is recognised globally for his leadership and successful impact across a wide platform of healthcare arenas.
Emmet Browne, CEO of Nuritas, said, “As our opportunity is great so are the decisions that lie before us as we scale up. George’s depth of experience, knowledge and wisdom, gained at the highest levels of healthcare leadership, will be a huge addition to us as we deliver on the huge potential that lies within Nuritas. I am delighted to welcome George on board and we all look forward to working with him in the exciting years ahead.
Nuritas also announced today that it had filled two key positions on its Advisory Board in the vital areas of strategic translational science and food/product regulation.
The first of these appointments is Dr Dominique Bridon who has over 25 years of experience in therapeutic discovery, translational research and formulation. More precisely Dominique is an expert in peptide development and commercialisation which is at the core of Nuritas. He has had various roles such as Head of Research and Development in multinational pharmaceutical companies working with Ipsen and Pharmacia as well as being a co-founder of a biotech start-up.
An expert in regulatory affairs in the EU, Steve Morrison has also been added to the Advisory Board and brings over 20 years of regulatory experience in both the pharma and food areas. He is currently the Managing Director of P2F (Pharma to Food) Ventures Limited and was formerly the Chief Operating Officer of Provexis which was the first European Company to achieve an Article 13.5 EFSA health claim.
Founder and Chief Scientific Officer, Dr Nora Khaldi stated,“I am delighted George, Dominique and Steve are joining us. From our first meetings it was clear that all three shared our passion for delivering life-changing ingredients. We are continuing to build a world-class team to help us realise our vision of Nuritas ingredients reaching 1 billion people by 2020.”
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.